Noxopharm White Paper

13 Disclaimer: Veyonda is currently not approved in Australia or any other country Veyonda® – CEP program CEP: Chemotherapy Enhancement Program CEP aims: To demonstrate that in advanced solid tumours poorly sensitive or refractory to chemotherapy that... • Veyonda plus standard chemotherapy is a more effective treatment compared to chemotherapy alone. • The chemo-enhancing functions of Veyonda allow the use of lower dosages of chemotherapy, providing considerable safety benefits, while still achieving similar or greater efficacy outcomes to standard dose chemotherapy. CEP rationale: • Most cancers either show inherently low sensitivity to chemotherapy, or develop insensitivity (refractory cancers), through expression of multi-drug resistance (MDR) mechanisms. • The oncotoxic properties of idronoxil inhibit MDRs, restoring sensitivity to a wide range of commonly-used chemotherapies including taxanes, platinums and anthracyclines. • The immunological properties of idronoxil lead to an increased number of immune cells infiltrating the tumors, off-setting the toxic effect of most chemotherapies on lymphoid cell numbers and function. CEP program objectives: To show that... • Veyonda does not exacerbate chemotherapy toxicity. • A combination of Veyonda and a drug drawn from the taxane, platinum or anthracycline families of chemotherapies provides meaningful survival outcomes in cancer types typically poorly responsive to those chemotherapies alone. • Combining Veyonda with a drug drawn from the taxane, platinum or anthracycline families of chemotherapies allows that chemotherapy to be used at a dosage lower than normal, and thereby likely associated with fewer toxic side-effects, without compromising the efficacy of the therapy.